Bayer Korea's Vitrakvi and Roche Korea's Rozlytrek completed drug price negotiations and are likely to register their benefits in April. Both drugs are used to treat solid cancer in adults and children with confirmed NTRK gene fusion. If NTRK gene fusion is confirmed, it can be administered regardless of cancer.

According to the industry on the 21st, the two drugs are likely to complete drug price negotiations with NHIS and register their benefits in April. Rozlytrek and Vitrakvi were granted permission in April 2020 and May 2020, respectively.

Rozlytrek and Vitrakvi are equally used in adult and pediatric solid cancer treatments with neurotic tyrosine receptor kinase (NTRK) gene fusion.